3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
21
Phase EARLY_PHASE1
1
Phase 3
1
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
4
Other hematologic neoplasm
3
Lymphoid
2
Breast
2
Tumor-Agnostic
1
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Gynecologic
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
1
Lung Neoplasms
1
Colonic Neoplasms
1
Interventions
Carboplatin
282
Cisplatin
225
Pemetrexed
196
Paclitaxel
151
Docetaxel
132
pembrolizumab
109
Gemcitabine
94
Etoposide
63
Erlotinib Hydrochloride
59
Radiotherapy
54
Vinorelbine
47
durvalumab
46
Gefitinib
46
Bevacizumab
46
atezolizumab
41
Nivolumab
40
Drug Therapy
34
osimertinib
30
Topotecan
29
tislelizumab
23
130-nm albumin-bound paclitaxel
23
Radiosurgery
21
Ipilimumab
18
Crizotinib
18
Magnetic Resonance Spectroscopy
15
Albumin-Bound Paclitaxel
15
Surgical Procedures, Operative
14
aumolertinib
13
Platinum
13
Injections
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Practice Guidelines as Topic
×
Thoracic
×
Clear all
NCT06563388
2026-02-04
ID-COMET
Roswell Park Cancer Institute
Phase 3
Recruiting
800 enrolled